Almirall's Nine-month 2023 Results:

BARCELONA, Spain, November 09, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.

Related Keywords

Austria ,Spain ,United States ,Germany ,United Kingdom ,Hong Kong ,Berlin ,Barcelona ,Comunidad Autonoma De Cataluna ,Taiwan ,Netherlands ,Denmark ,Italy ,Macau ,Switzerland ,China ,Spanish ,Chinese ,Omar Ram ,Epimab Biotherapeutics ,Astra Zeneca Covis ,Eli Lilly ,European Union ,Corporate Communications ,European Academy Of Dermatology ,European Medicines Agency ,Venereology Congress ,Simcere Pharmaceutical Group ,Spanish Stock Exchange ,Committee For Medicinal Products Human Use ,European Commission ,Simcere Pharmaceutical Group For ,Healthcare Products Regulatory Agency ,Chinese National Medical Products Administration ,European Association Of Dermatology ,Net Sales ,European Dermatology ,New Drug Application ,Astra Zeneca ,Net Debt ,Gallardo Piqu ,European Association ,Medicinal Products ,Human Use ,European Academy ,Global Assessment ,Eczema Area ,Severity Index ,Annual Fall Clinical Dermatology Conference ,Large Field ,Ichnos Science ,Greater China ,Mainland China ,Fabs In Tandem Immunoglobulin ,Noble Purpose ,Safe Treatment ,Psoriatic Disease ,Real World Prospective Cohort Study ,Patient Reported Outcomes ,Tirbanibulin Effectiveness ,Cutaneous Medicine ,Lebrikizumab Is Maintained ,Two Years ,Clinical Dermatology ,Almirall ,Psoriasis ,Plaque Psoriasis ,Lebrikizumab ,M ,Uropean Academy Of Dermatology And Venereology ,